Dynocardia

The NHLBI selected ViTrack to address hypertensive disorders of pregnancy, which pose a growing threat, particularly among Black patients and other patients of color who face disproportionate maternal mortality and severe maternal morbidity.

The company seeks a senior algorithm engineer for image processing and machine learning to design, develop, and implement algorithms and imaging tools for blood pressure and hemodynamic monitoring applications.

The company seeks a senior mechanical engineer to help design and develop a continuous blood pressure measurement device, with hands-on work and technical leadership responsibilities.

The company seeks a senior software and algorithms engineer to help design and develop a continuous blood pressure measurement device, with hands-on work and technical leadership responsibilities.

ViTrack technology is described as providing accurate, continuous non-invasive systolic and diastolic blood pressure monitoring from a wrist-worn device without user, caregiver, or healthcare provider participation; it has undergone bench testing and ongoing ICU clinical studies.

Potential applications span multiple markets, including hospital, clinical practice, remote patient monitoring, consumer wellness, and disease prevention.

Dynocardia secures a **$1 million NSF grant** to advance its **computer vision-based motion-correction technology** and broaden applications for **ViTrack**, a continuous non-invasive blood pressure (CNIBP) monitor. The funding supports enhancements to the company’s proprietary motion-tracking algorithms, improving accuracy in dynamic environments like hospitals or ambulances. ViTrack’s non-invasive approach eliminates the need for cuff-based measurements, addressing a key gap in real-time patient monitoring.

Dec 2024PR NewswireNews article

Dynocardia and NYC Health + Hospitals receive a **$2.3 million NIH grant** to study **ViTrack**, a wearable device tracking blood pressure and heart rate. The non-invasive monitor aims to improve early detection of maternal and infant health risks during pregnancy. The research, funded by the National Heart, Lung, and Blood Institute, evaluates ViTrack’s potential in clinical settings.

Mar 2024Femtech InsiderNews article

The National Institutes of Health (NIH) awards **Dynocardia** $2.3 million to assess how **ViTrack**, a non-invasive wearable blood pressure and heart monitor, affects maternal and child health outcomes during pregnancy. The study partners with **NYC Health + Hospitals** to evaluate the device’s real-world performance in high-risk pregnancies. ViTrack’s continuous monitoring aims to improve early detection of complications like preeclampsia.

Feb 2024PR NewswireNews article

Dynocardia develops a cuff-less, non-invasive device for continuous blood pressure monitoring. The company aims to advance cardiovascular health solutions globally. Co-founder and CEO Mohan Thanikachalam, M.D., leads the effort with a medical background.

Aug 2021LuminateNews article